MarketResearchReports.biz has added the ‘OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis And Forecasts To 2024’ report to its offering. This study on acute myeloid leukemia presents the major trends and the prominent risk factors associated with acute myeloid leukemia in the 7mm, including the USA, France, Germany, Italy, Spain, the UK, and Japan. The study also covers chief topics such as market characterization, competitor assessment, clinical trial mapping, unmet needs, and key implications of the market for AML therapeutics. In addition, the pipeline analysis section of the report includes extensive data assessing trends, along with mentioning mechanisms of action under development for various lines of therapy. The report also provides an analysis of the future and the current market competition within the global AML therapeutics market.
As per the report, the sales of AML therapeutics stood at $342 mn within the 7mm in 2014. It is anticipated that the market will almost triple in the forecast horizon and will reach $932 mn by 2024. It will expand at a 10.50% CAGR from 2014 to 2024. The report commences by providing a disease overview. In this section of the report, the etiology as well as pathophysiology of acute myeloid leukemia is provided, along with presenting its classification. This section also throws light on the symptoms, disease background, and epidemiology related to acute myeloid leukemia.
Acute myeloid leukemia is a type of cancer of the bone marrow and blood. The word ‘acute’ refers to the rapid progression of this type of cancer. It is known as myeloid leukemia due to the fact that it impacts a group of white blood cells. These white blood cells are called as myeloid cells and they usually develop into numerous kinds of mature blood cells including platelets, white blood cells, and red blood cells.
The report further throws light on the key risk factors as well as comorbidities related to acute myeloid leukemia. The chief risk factors include the rising age of the patients, resulting in increased risk as well as worsened prognosis, smoking, increasing occurrence especially in Italy and Spain, and the rising risk of acute myeloid leukemia by the intake of benzene, post-radiation therapies, and chemotherapy. As per the report, a number of new branded therapies including Volasertib, Vyxeos, and CC-486 are poised to lead the market in addition to the generic azacitidine. Market dynamics such as the growth drivers as well as inhibitors have also been elaborated upon in the next section of the study.
As per the report, the rising occurrence of AML is the prime factor fuelling the market for acute myeloid leukemia. In addition, the increasing uptake and approval of premium-priced products including FLT3 kinase inhibitors such as midostaurin and quizartinib as well as PI3 kinase inhibitors such as volasertib, along with new formulations of the already present chemotherapies including CC-486, Vyxeos, and guadecitabine, are also boosting the growth of the market. On the other hand, the prime unmet requirement in the market is the need for effective treatment options for the treatment of aged AML patients. This may have a negative impact on the growth of the market. In addition, the current AML pipeline being weak on the basis of efficacy is also a prime factor that may inhibit the growth of the market.
To order report Call Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org